Sustainability | November 01, 2024
Lupin to develop inhalers with near-zero global warming potential propellants
Lupin's R&D teams are working on products with a near-zero global warming potential propellant
Lupin's R&D teams are working on products with a near-zero global warming potential propellant
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
MedGenome reaffirms its commitment to broaden access to quality and affordable genetic solutions for all
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
Wockhardt's yet another novel antibiotic Miqnaf receives favourable recommendation from Subject Expert Committee of CDSCO
Biotin Sublingual Spray and Melatonin Sublingual Spray to help consumers tackle health issues that come with today’s fast-paced life
WEF recognises company’s Bharuch manufacturing facility as a global manufacturing lighthouse
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
Subscribe To Our Newsletter & Stay Updated
